ENX-104

Last updated

ENX-104
ENX-104.svg
Clinical data
Other namesENX104; Deuterated nemonapride enantiomer [1]
Routes of
administration 		Oral [2]
Drug class Dopamine D2 and D3 autoreceptor antagonist
Identifiers
  • 5-chloro-N-[(2S,3S)-1-[dideuterio(phenyl)methyl]-2-methylpyrrolidin-3-yl]-2-methoxy-4-(trideuteriomethylamino)benzamide
PubChem CID
Chemical and physical data
Formula C21H21ClD5N3O2
Molar mass 392.94 g·mol−1
3D model (JSmol)
  • [2H]C([2H])([2H])NC1=CC(OC)=C(C(N[C@@H](CC2)[C@H](C)N2C([2H])([2H])C3=CC=CC=C3)=O)C=C1Cl
  • InChI=InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)/t14-,18-/m0/s1/i2D3,13D2
  • Key:KRVOJOCLBAAKSJ-KBBDZWSESA-N

ENX-104, also known as deuterated nemonapride enantiomer, [1] is a selective dopamine D2 and D3 receptor antagonist which is under development for the treatment of major depressive disorder. [2] [3] [4] [5] [6] It is specifically under development for the treatment of major depressive disorder characterized by anhedonia. [4] [2] The drug is being developed for use at low doses to preferentially block presynaptic dopamine D2 and D3 autoreceptors and hence to enhance rather than inhibit dopaminergic neurotransmission. [2] [4] [7] [5] [6] It is taken by mouth. [2]

Contents

Pharmacology

Pharmacodynamics

ENX-104 is intended for use at low doses to produce preferential presynaptic dopamine D2 and D3 autoreceptor antagonism and consequent enhancement of dopaminergic neurotransmission. [2] [4] [7] [5] [6] The target occupancy of the dopamine D2 and D3 receptors is approximately 40 to 70%. [5] [6] For comparison, dopamine D2 receptor occupancy of 65 to 80% is associated with antipsychotic-like effects and hence with substantial postsynaptic dopamine D2 receptor antagonism in animals. [8] [9] ENX-104 has been found to increase dopamine and serotonin levels in the nucleus accumbens and prefrontal cortex. [6] It was also found to augment amphetamine-induced dopamine release. [6] In accordance with these findings, the drug was found to produce anti-anhedonia-like effects, specifically increased reward responsiveness, in animals. [5] Low doses of amisulpride likewise showed anti-anhedonia-like effects. [5]

ENX-104 is not expected to induce motor side effects like extrapyramidal symptoms (EPS) or catalepsy at the low doses employed, as these effects require higher occupancy of the D2 receptor (e.g., ~80%). [5]

ENX-104 is highly potent as a dopamine receptor antagonist. [5] Its affinities are 0.01 nM for the dopamine D2L receptor, 0.1 nM for the dopamine D2S receptor, 0.2 nM for the dopamine D3 receptor (2- to 20-fold lower than for the D2 receptor), and 1.6 nM for the dopamine D4 receptor (8- to 160-fold lower than for the D2 receptor). [5] [6] The drug is also a weak partial agonist or antagonist of the serotonin 5-HT2A receptor, with an EC50 Tooltip half-maximal effective concentration of 14 nM (70- to 1,400-fold lower than its affinity for the D2 receptor) and an Emax of approximately 40%. [5] Conversely, ENX-104 showed little or no functional activity at the serotonin 5-HT1A or 5-HT7 receptor. [5]

Chemistry

ENX-104 is a benzamide derivative. [2] [10] It is a partially-deuterated analog of the drug nemonapride, which is used to treat schizophrenia. [11] [12] [1]

Clinical trials

As of September 2024, ENX-104 is in phase 1 clinical trials for major depressive disorder. [2] [4] [7] It is under development by Engrail Therapeutics. [2] [4]

See also

Related Research Articles

<span class="mw-page-title-main">Atypical antipsychotic</span> Class of pharmaceutical drugs

The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval for schizophrenia, bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder.

<span class="mw-page-title-main">Aripiprazole</span> Atypical antipsychotic

Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic. It is primarily used in the treatment of schizophrenia and bipolar disorder; other uses include as an add-on treatment in major depressive disorder and obsessive–compulsive disorder (OCD), tic disorders, and irritability associated with autism. Aripiprazole is taken by mouth or via injection into a muscle. A Cochrane review found low-quality evidence of effectiveness in treating schizophrenia.

<span class="mw-page-title-main">Dopamine antagonist</span> Drug which blocks dopamine receptors

A dopamine antagonist, also known as an anti-dopaminergic and a dopamine receptor antagonist (DRA), is a type of drug which blocks dopamine receptors by receptor antagonism. Most antipsychotics are dopamine antagonists, and as such they have found use in treating schizophrenia, bipolar disorder, and stimulant psychosis. Several other dopamine antagonists are antiemetics used in the treatment of nausea and vomiting.

<span class="mw-page-title-main">Dopaminergic</span> Substance related to dopamine functions

Dopaminergic means "related to dopamine", a common neurotransmitter. Dopaminergic substances or actions increase dopamine-related activity in the brain.

<span class="mw-page-title-main">Chlorprothixene</span> Typical antipsychotic medication

Chlorprothixene, sold under the brand name Truxal among others, is a typical antipsychotic of the thioxanthene group.

<span class="mw-page-title-main">Amisulpride</span> Atypical antipsychotic and antiemetic medication

Amisulpride, sold under the brand names Solian and Barhemsys, is a medication used in the treatment of schizophrenia, acute psychotic episodes, depression, and nausea and vomiting. It is specifically used at lower doses intravenously to prevent and treat postoperative nausea and vomiting; at low doses by mouth to treat depression; and at higher doses by mouth to treat psychosis.

<span class="mw-page-title-main">Piribedil</span> Drug used in the management of Parkinsons disease

Piribedil (trade names Pronoran, Trivastal Retard, Trastal, Trivastan, Clarium and others) is an antiparkinsonian agent and piperazine derivative which acts as a D2 and D3 receptor agonist. It also has α2-adrenergic antagonist properties.

<span class="mw-page-title-main">Pipamperone</span> Antipsychotic drug

Pipamperone, sold under the brand name Dipiperon, is a typical antipsychotic of the butyrophenone family used in the treatment of schizophrenia and as a sleep aid for depression. It is or has been marketed under brand names including Dipiperon, Dipiperal, Piperonil, Piperonyl, and Propitan. Pipamperone was discovered at Janssen Pharmaceutica in 1961, and entered clinical trials in the United States in 1963.

<span class="mw-page-title-main">Nemonapride</span> Antipsychotic medication

Nemonapride, also previously known as emonapride and sold under the brand name Emilace, is an atypical antipsychotic which is used in the treatment of schizophrenia. It is taken by mouth.

<span class="mw-page-title-main">Pimavanserin</span> Atypical antipsychotic medication

Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis. Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist, but rather is a selective inverse agonist of the serotonin 5-HT2A receptor.

<span class="mw-page-title-main">Roxindole</span> Dopaminergic & serotonergic drug developed for schizophrenia treatment

Roxindole (EMD-49,980) is a dopaminergic and serotonergic drug which was originally developed by Merck KGaA for the treatment of schizophrenia. In clinical trials its antipsychotic efficacy was only modest but it was unexpectedly found to produce potent and rapid antidepressant and anxiolytic effects. As a result, roxindole was further researched for the treatment of depression instead. It has also been investigated as a therapy for Parkinson's disease and prolactinoma.

<span class="mw-page-title-main">Sarizotan</span> Chemical compound

Sarizotan (EMD-128,130) is a selective 5-HT1A receptor agonist and D2 receptor antagonist, which has antipsychotic effects, and has also shown efficacy in reducing dyskinesias resulting from long-term anti-Parkinsonian treatment with levodopa.

<span class="mw-page-title-main">Cariprazine</span> Atypical antipsychotic medicine

Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, which is used in the treatment of schizophrenia, bipolar mania, bipolar depression, and major depressive disorder. It acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. Cariprazine is also a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors, with high selectivity for the D3 receptor. It is taken by mouth. The most prevalent side effects include nausea, mild sedation, fatigue, and dizziness. At higher dosages, there is an increased risk for restlessness, insomnia, and tremors.

<span class="mw-page-title-main">F-15063</span> Chemical compound

F-15,063 is an orally active potential antipsychotic, and an antagonist at the D2/D3 receptors, partial agonist at the D4 receptor, and agonist at the 5-HT1A receptors. It has greater efficacy at the 5-HT1A receptors than other antipsychotics, such as clozapine, aripiprazole, and ziprasidone. This greater efficacy may lead to enhanced antipsychotic properties, as antipsychotics that lack 5-HT1A affinity are associated with increased risk of extrapyramidal symptoms, and lack of activity against the negative symptoms of schizophrenia.

<span class="mw-page-title-main">Brexpiprazole</span> Atypical antipsychotic

Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.

<span class="mw-page-title-main">Mesdopetam</span> Chemical compound

Mesdopetam (INNTooltip International Nonproprietary Name; developmental code names IRL-790, IPN60170) is a dopamine D2 and D3 receptor antagonist with preference for the D3 receptor which is under development for the treatment of Parkinson's disease, drug-induced dyskinesia, and psychotic disorders. It has been described by its developers as having "psychomotor stabilizing" properties.

<i>N</i>-Methylamisulpride Experimental antipsychotic

N-Methylamisulpride (developmental code name LB-102) is a dopamine D2 and D3 receptor antagonist and serotonin 5-HT2B and 5-HT7 receptor antagonist which is under development for the treatment of schizophrenia. It is a benzamide derivative and is the N-methylated analogue of amisulpride. The drug is being developed for use both orally and parenterally.

<span class="mw-page-title-main">ENX-105</span> Chemical compound

ENX-105 is an investigational new drug being developed by Engrail Therapeutics for the treatment of post-traumatic stress disorder (PTSD). It is currently in the preclinical stage, trailing behind a closely related Engrail compound, ENX-104, which is focused on depression and anhedonia.

References

  1. 1 2 3 "Engrail Therapeutics Corporate-Summary: 1Q 24" (PDF). Retrieved 2024-10-24.
  2. 1 2 3 4 5 6 7 8 9 "ENX 104". AdisInsight. 27 September 2024. Retrieved 22 October 2024.
  3. ↑ "Delving into the Latest Updates on ENX-104 with Synapse". Synapse. 13 October 2024. Retrieved 22 October 2024.
  4. 1 2 3 4 5 6 "Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia". markets.businessinsider.com. 18 September 2024. Retrieved 22 October 2024.
  5. 1 2 3 4 5 6 7 8 9 10 11 Vadodaria K, Kangas BD, Garvey DS, Brubaker W, Pizzagalli DA, Sudarsan V, et al. (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P351. Anti-Anhedonic Profile of ENX-104, a Novel and Highly Potent Dopamine D2/3 Receptor Antagonist". Neuropsychopharmacology. 47 (Suppl 1): 220–370 (265–266). doi:10.1038/s41386-022-01485-0. PMC   9714399 . PMID   36456694.
  6. 1 2 3 4 5 6 7 Vadodaria K, Serrats J, Brubaker W, Sudarsan V, Vanover K (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 - P500: P356. ENX-104, a Novel and Potent D2/3 Receptor Antagonist, Increased Extracellular Levels of Dopamine and Serotonin in the Nucleus Accumbens and Prefrontal Cortex of Freely-Moving Rats". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (271–272). doi:10.1038/s41386-023-01756-4. PMC  10729596. PMID   38040810.
  7. 1 2 3 Engrail Therapeutics (18 September 2024). "Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia". GlobeNewswire News Room (Press release). Retrieved 22 October 2024.
  8. ↑ Wadenberg ML (January 2010). "Conditioned avoidance response in the development of new antipsychotics". Curr Pharm Des. 16 (3): 358–370. doi:10.2174/138161210790170085. PMID   20109144.
  9. ↑ Wadenberg ML, Hicks PB (1999). "The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?". Neurosci Biobehav Rev. 23 (6): 851–862. doi:10.1016/s0149-7634(99)00037-8. PMID   10541060.
  10. ↑ "ENX-104 boosts dopamine and serotonin in rat brain". BioWorld. Clarivate.
  11. ↑ WO 2023130119,Vadodaria K, Vanover K, Serrats J, Sudarsan V, Garvey D,"Preparation of deuterated pyrrolidin derivatives as modulators of dopamine and serotonin neurotransmission useful in treatment of diseases", assigned to Engrail Therapeutics, Inc.
  12. ↑ Shun-ichiro U, Yusuke S, Shogo M, Naoki K, Yoshiharu I (2017). "Concise, Protecting-Group-Free Synthesis of (+)-Nemonapride via Eu(OTf)3-Catalyzed Aminolysis of 3,4-Epoxy Alcohol". Chemical & Pharmaceutical Bulletin. 65 (1). Pharmaceutical Society of Japan: 22–24. doi: 10.1248/cpb.c16-00568 . ISSN   0009-2363. PMID   28049911.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.